Disclosed is a use of a growth hormone (GH) variant having GH antagonistic activity, and an oligonucleotide 8 to 80 nucleobases in length targeted to a nucleic acid encoding growth hormone receptor (GHR) so as to inhibit expression of the GHR thereby reducing the level of IGF-I in a subject, in the manufacture of a preparation for the treatment or prevention of a disease caused by and/or associated with an increased level of insulin-like growth factor I (IGF-I), and wherein the GH variant and the oligonucleotide are in separate preparations or in a single preparation.
